Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramiprin vs Tritace in Essential Hypertension
NCT00366119Phase 4Unknown
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ramipril in essential hypertension (2 arms). Primary endpoint: Reduction of Diastolic Blood Pressure. Status: unknown.
02
Drugs
ramipril
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00366119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00366119.